ArticleCellular oncology (Dordrecht, Netherlands)2025
TRIM47-facilitated PLK1 stabilization promotes the proliferation of liver cancer cells.
Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLiver cancer (LC) remains a leading cause of cancer-related mortality worldwide, with limited therapeutic options for advanced-stage disease. While tripartite motif-containing 47 (TRIM47), a typical E3 ubiquitin ligase, has been implicated in cancer progression, its precise role in LC pathogenesis remains unclear.
methodsTRIM47 expression in hepatocellular carcinoma (HCC) tissues was analyzed through public databases. Functional assays, including TRIM47 knockdown and overexpression experiments, were performed to investigate its impact on cell proliferation, apoptosis and the cell cycle both in vitro and in vivo. The investigation was conducted using a combination of methodologies, including yeast-two hybrid screening, ubiquitination assays, and signaling pathway analyses, to elucidate the underlying mechanisms. In addition, rescue assays were performed to validate the effect of TRIM47-PLK1 axis on LC growth.
resultsTRIM47 was significantly elevated in HCC tissues and positively correlated with advanced clinical stage and poor overall survival. Functionally, TRIM47 knockdown suppressed LC cell growth, while its overexpression promoted tumor proliferation. Furthermore, TRIM47 facilitates cell cycle progression by alleviating G2/M phase arrest and inhibits apoptosis in LC cells. Mechanistically, TRIM47 catalyzes K63-linked ubiquitination of polo-like kinase 1 (PLK1), leading to its stabilization and subsequent activation of the NF-κB and MAPK pathways. Clinical validation confirmed a significant positive correlation between TRIM47 and PLK1 expression in human HCC specimens. Importantly, pharmacological inhibition of PLK1 effectively abrogated TRIM47-driven tumor growth in xenograft models.
conclusionThis study identifies TRIM47 as a critical regulator of LC progression through PLK1 stabilization and proposes the TRIM47-PLK1 axis as a potential therapeutic target for LC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.